+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.

Age: 18Years - 99YearsAll GendersPhase 3
686 locations
E

Actively Recruiting

Researchers are evaluating the investigational drug omecamtiv mecarbil to see if it can reduce the risk of serious effects related to heart failure, such as hospitalization, heart transplantation, or death, in patients with symptomatic heart failure with severely reduced ejection fraction HFrEF. This Phase 3 trial compares the safety and effectiveness of omecamtiv mecarbil against a placebo in patients with this condition. Participants will be randomly assigned to receive either omecamtiv mecarbil or a placebo. Those in the omecamtiv mecarbil group will take oral tablets twice daily with doses adjusted based on drug levels in their blood 25, 37.5, or 50 mg. The treatment continues until at least 850 participants experience a heart failure event or cardiovascular death. This is a double-blind study, meaning neither participants nor study staff know who receives the drug or placebo. During the study, participants will be monitored up to about 3 years. Researchers will track occurrences of cardiovascular death, heart failure events, device implantations, heart transplants, and strokes. Participants will have regular visits and assessments to monitor their health and study outcomes. Safety and efficacy data will be collected until the study concludes when the required number of events has occurred.

Age: 18Years - 85YearsAll GendersPhase 3
213 locations